AKR1C2
MOLECULAR TARGETaldo-keto reductase family 1 member C2
AKR1C2 (aldo-keto reductase family 1 member C2) is targeted by 13 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting AKR1C2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | flurbiprofen | 4.33 | 75 |
| 2 | caffeic acid phenethyl ester | 4.25 | 69 |
| 3 | flufenamic acid | 4.14 | 62 |
| 4 | mefenamic acid | 3.93 | 50 |
| 5 | meclofenamic acid | 3.50 | 32 |
| 6 | dexibuprofen | 3.00 | 19 |
| 7 | fenamic acid | 2.71 | 14 |
| 8 | baccharin | 2.08 | 7 |
| 9 | 6 methoxy 2 naphthylacetic acid | 1.79 | 5 |
| 10 | jasmonic acid | 1.79 | 5 |
| 11 | Medroxyprogesterone Acetate | 1.39 | 3 |
| 12 | Naproxen | 1.10 | 2 |
| 13 | Berberine | 0.69 | 1 |
About AKR1C2 as a Drug Target
AKR1C2 (aldo-keto reductase family 1 member C2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 13 compounds with documented AKR1C2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
AKR1C2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.